Sign In   |   Register
News: Congress

VIDEO: Identifying the very high risk patient with recurrent events in FOURIER

28 April 2017  
Share |

The results of GLAGOV and FOURIER clearly show that lowering plasma LDL cholesterol levels to very low levels with the PCSK9 inhibitor evolocumab induces plaque regression and reduces cardiovascular events in high risk patients. Despite this, some patients still progress and suffer events. Why is that, and how can we identify these patients? Professor Stephen Nicholls (University of Adelaide, Australia) provides some insight.

 


Membership Software Powered by YourMembership  ::  Legal